There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hookipa Pharma (HOOK – Research Report) ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...
Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Thank you for standing by. Welcome to the Merck & Co. Q3 sales and earnings conference call. (Operator Instructions) This call is being recorded. If you have any objections, you may disconnect at this ...
In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...
Cantor Fitzgerald raised the firm’s price target on Riot Platforms (RIOT) to $24 from $22 and keeps an Overweight rating on the shares. Riot’s Q3 revenue was was relatively in line with the ...
Louise Bower is a Chartered Accountant with over 25 years of experience in senior executive roles across varied industry sectors and jurisdictions including Australia, South Africa and the United ...
On Wednesday, Cantor Fitzgerald adjusted its 12-month price target on shares of Udemy Inc (NASDAQ:UDMY), an online learning platform, to $11.00 from the previous target of $18.00. Despite the ...
Mikael Dolsten; Chief Scientific Officer & President, Pfizer Research and Development; Pfizer Inc Andrew Baum; Chief Strategy and Innovation Officer & Executive Vice President; Pfizer Inc Louise Chen; ...
Pfizer Inc Louise Chen; Analyst; Cantor Fitzgerald & Co. Inc. Geoff Meacham; Analyst; Citigroup Inc. (Operator Instructions) Good day, everyone, and welcome to Pfizer's third-quarter 2024 earnings ...